Gastroenterology Associates of Western Michigan, P.L.C.

Summary

Gastroenterology Associates of Western Michigan, P.L.C. is a medical facility located in Wyoming, Michigan. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Colitis, Gastroparesis, Non-alcoholic Fatty Liver Disease and other specialties. Gastroenterology Associates of Western Michigan, P.L.C. is involved with conducting 54 clinical trials across 52 conditions. There are 1 research doctors associated with this hospital, such as Allan Coates, MD.

Top PIs

Clinical Trials running at Gastroenterology Associates of Western Michigan, P.L.C.

Crohn's Disease

Ulcerative Colitis

Colitis

Nonalcoholic Steatohepatitis

Type 2 Diabetes

Non-alcoholic Fatty Liver Disease

Crohn's disease

Gastrointestinal Diseases

Congenital Hepatobiliary Disorders

Outpatient Colonoscopy

Vedolizumab

for Ulcerative Colitis and Crohn's Disease

Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 months (14 weeks) of treatment with Vedolizumab (this is called remission). Participants will be treated with Vedolizumab for approximately 1 year (50 weeks). During the first 1.5 months (6 weeks), participants will receive Vedolizumab as an infusion in the vein (called intravenously). After this, participants will receive Vedolizumab as an injection under the skin (called subcutaneously) for the rest of the treatment. Participants for whom the treatment does not seem to work well after 3.5 months (14 weeks) will stop treatment with Vedolizumab and can change to another treatment and also there will be additional required visits at 6 months (26 weeks) and at 1 year (52 weeks). All participants will be checked again 4.5 months (18 weeks) after their last treatment with Vedolizumab. During the study, participants will visit their study clinic several times.

Recruiting

3 awards

Phase 4

2 criteria

SAR442970

for Crohn's Disease

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

Recruiting

0 awards

Phase 2

1 criteria